Allen & Overy on the combination between Biolog-id and SPAC Genesis Growth Tech Acquisition Corp
Related people
Press contacts
For media enquiries relating to this topic, please contact:
Headlines in this article
Related news and insights
News: 09 February 2024
Allen & Overy advises Sartorius group on EUR1.4bn equity raising
News: 18 January 2024
News: 18 January 2024
Allen & Overy has advised Genesis Growth Tech Acquisition Corp, a Nasdaq-listed Special Purpose Acquisition Company ("SPAC"), in connection with the negotiation of a Business Combination Agreement relating to a proposed merger with Biolog-id, a global leader in the development and service of identification and traceability solutions for blood products and injectable therapeutic preparations in oncology.
This merger will create a publicly traded digital health solutions company focused on value chain optimization.
The transaction values Biolog-id at $312 million and is scheduled for the first quarter of 2023. Following the merger, Biolog-id will be listed on Nasdaq under the symbol “BGID”.
The Allen & Overy team in Paris was composed of Olivier Thébault (Partner), Alexandre Ancel (Partner), Anne-Caroline Payelle (Counsel), Jade Billère-Mellet and Myriam Azmy (Associates).